Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Professor Dr Hans-Georg Rammensee Awarded the Bayer Hansen Family Award 2013

Published: Friday, March 08, 2013
Last Updated: Friday, March 08, 2013
Bookmark and Share
Prestigious Hansen Family Award recognizes Hans-Georg Rammensee’s pioneering scientific research activities.

immatics biotechnologies GmbH has announced that the Company’s scientific inspirer and co-founder Professor Dr Hans-Georg Rammensee has been awarded the Hansen Family Award 2013 for his contribution to the advancement of cancer immunotherapy.

Hans-Georg Rammensee received his award at a ceremony in Berlin last night.

The Hansen Family Award was established in 2000 by Professor Kurt Hansen, former chairman of Bayer’s Management and Supervisory Board, to recognize medical achievements in German-speaking countries.

The award, which carries a prize money of 75.000 EUR, is presented every two years in alternation with the Otto Bayer Award and acknowledges innovative research in areas related to medical science and medicine.

This year the Hansen Family Award recognizes the contribution of Hans-Georg Rammensee to the field of immunology and particularly its translation into patient treatment as recently published in Nature Medicine by immatics, the University of Tuebingen and co-workers.

Hans-Georg Rammensee is Head of immatics’ Scientific Advisory Board and co-founder of the Company. He is currently Head of the Department of Immunology at the University of Tuebingen.

His work on major histocompatibility complex (MHC) molecules, which play a vital role in immune responses, and associated peptides is considered a cornerstone in the history of immunology.

He has authored more than 250 papers, many thereof published in journals like Nature and Science, and has co-edited several journals including Immunogenetics, Cellular and Molecular Life Science and European Journal of Immunology.

He has received numerous well known scientific awards for his work, e.g. the Gottfried Wilhelm Leibniz Prize 1992, the Robert Koch Prize 1993, and the Paul Ehrlich and Ludwig Darmstaedter Prize 1996.

Dr Harpreet Singh, Chief Scientific Officer of immatics, said: “We are delighted that Hans-Georg has been recognized again for his pioneering contribution to immunology which has formed the basis of immatics’ innovative approach to developing therapeutic cancer vaccines. immatics has made significant progress with its lead vaccine IMA901 for advanced kidney cancer - progress that would have not been possible without the groundbreaking work by Hans-Georg.”

Professor Dr Hans-Georg Rammensee said: “I am thrilled to have received this award as the representative of a highly skilled and motivated team of researchers over the years. I am also very happy to see the progress that immatics has made in advancing its multi-peptide cancer vaccine IMA901 for the treatment of renal cancer patients. We have seen very encouraging results with this vaccine in the phase 2 trial making us believe that this approach has the potential to change the treatment of renal cancer, and most likely of other cancers as well, significantly.”

“Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival,” Walter S., Weinschenk T. et al. (2012) Nature Medicine. Published online: 29 July 2012.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines
Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC).
Thursday, October 16, 2014
immatics Receives €22 Million Final Tranche of Series D Fundraising
Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics’ Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies.
Thursday, July 17, 2014
Immatics to Continue Work on Vaccine (IMA950) for Glioblastoma
A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a trial conducted by Cancer Research UK.
Thursday, April 24, 2014
immatics Closes €34 Million Financing
immatics’ lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015.
Tuesday, October 15, 2013
immatics Presents Encouraging Overall Survival Data from a Phase 2 Study in CRC
T-cell responses to the IMA910 colorectal cancer vaccine peptides show a clear correlation with longer overall survival.
Monday, June 04, 2012
immatics Wins 2012 TiE50 Award
immatics chosen as a leading company in the life sciences category by the world's largest entrepreneurial network.
Friday, May 25, 2012
immatics Appoints Dr Rainer Kramer as CBO
Dr. Kramer will lead immatics’ business development unit.
Thursday, April 12, 2012
immatics Presents Positive Phase II Results with IMA910 in CRC Patients
Study shows a consistent association between immune response to IMA910 and all clinical endpoints and an excellent tolerability profile.
Wednesday, January 25, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
New Mussel-Inspired Surgical Protein Glue
Korean scientists have developed a light-activated, mussel protein-based bioadhesive that works on the same principles as mussels attaching to underwater surfaces and insects maintaining structural balance and flexibility.
Web App Helps Researchers Explore Cancer Genetics
Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!